Related Experiment Video

Updated: Jun 27, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Monitoring for lack of benefit: a critical component of a randomized clinical trial

Boris Freidlin1, Edward L Korn

  • 1Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA. freidlinb@ctep.nci.nih.gov

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|December 10, 2008
PubMed

Insights

Monitoring randomized clinical trials for lack of benefit is crucial, especially in lethal diseases like cancer. A more aggressive monitoring approach could improve many cancer trials, but caution is needed to avoid stopping trials prematurely.

Area of Science:

  • Clinical Trials
  • Oncology
  • Biostatistics

Background:

  • Randomized clinical trials (RCTs) require formal monitoring for early indications of benefit or lack thereof.
  • Monitoring is particularly critical in lethal diseases like cancer due to toxic therapies and limited efficacy data.

Purpose of the Study:

  • To review the complexities of stopping RCTs for lack of benefit.
  • To advocate for a more aggressive monitoring strategy in cancer trials.
  • To highlight potential issues with current monitoring guidelines.

Main Methods:

  • Review of existing literature and methodologies for clinical trial monitoring.
  • Analysis of the decision-making process for trial cessation due to futility.
  • Discussion of statistical considerations in interim analyses.

Main Results:

  • Many cancer trials could benefit from enhanced monitoring for lack of efficacy.
  • Current monitoring guidelines may lead to premature trial closure, potentially missing moderate treatment effects.

Conclusions:

  • A more proactive approach to monitoring for lack of benefit in cancer trials is recommended.
  • Careful consideration of monitoring guidelines is necessary to balance patient safety with the need for robust evidence.
  • Further research into optimal trial monitoring strategies is warranted.

Related Concept Videos

Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...